Novo CEO Doustdar 'Very Optimistic' About CagriSema

Fecha de publicación: 4 de noviembre de 2026, 9:39

Novo Nordisk A/S Chief Executive Officer Mike Doustdar discusses the possible launch of a new obesity drug called CagriSema. "We are hopeful that we will be able to get the timely approval from the FDA at the end of this year and launch it at the beginning of next year," Doustdar says. He speaks on…